Vulvovaginal Candidiasis

February 18, 2022

Patients with acute vulvovaginal candidiasis (VVC) greatly benefited from oral ibrexafungerp (Brexafemme, Scynexis), according to results of a global phase 3 randomized, double-blind, placebo-controlled superiority study published in the international journal of obstetrics and gynecology, BJOG.

February 16, 2022

Postmenopausal vaginal symptom severity is not significantly linked to vaginal microbiota or mucosal inflammatory markers, according to a small study in the American Journal of Gynecology & Obstetrics.

February 10, 2022

Scynexis released data from its pivotal Phase 3 CANDLE study of oral ibrexafungerp (BREXAFEMME) for the prevention of recurrent vulvovaginal candidiasis.

February 10, 2022

A different perspective on designing transfersomal nanocarriers of nystatin to treat vulvovaginal candidiasis (VVC) is reflected in a prospective in-vitro study in the journal Colloids and Surfaces B: Biointerfaces.

January 25, 2022

Research in the journal Cell Reports concludes that the discovery of a hormone-sensing pathway in Candida albicans, which enables the fungus to adapt to estrogen, could help explain gender biases linked to fungal infections and might provide an alternative approach to improving women's health.

January 25, 2022

Women with non-albicans Candida (NAC) vulvovaginal candidiasis (VVC) were nearly twice as likely to have multiple physician visits for recurring infections compared to women who had C. albicans (CA) VVC, according to a retrospective chart review in the Journal of Women’s Health.

January 25, 2022

An oral probiotic formula for the secondary prevention of vulvovaginal infections in pregnant women neither colonized in the vagina nor reduced the rate of repeated vulvovaginal infection, according to a study in the American Journal of Gynecology & Obstetrics.

January 19, 2022

A clinical study has confirmed that the pathophysiology of recurrent vulvovaginal candidiasis (RVVC) relies primarily on Candida albicans (C. albicans)-specific attributes like hyphal morphogenesis, biofilm formation and pathogenesis that differentiate it from other prominent non-albicans C. (NAC) species.

January 18, 2022

Among women with vulvovaginal candidiasis (VVC) or recurrent VVC (RVVC), the 3 most common signs and symptoms are itching (91.2%), burning (68.3%), and redness (58.1%), according to an online patient survey in BMC Womens Health.

January 18, 2022

Because the mechanism of action of medical-grade honey (MGH) is based on enhancing wound healing and exerting strong broad-spectrum antimicrobial activity, MGH may also help to treat recurrent vulvovaginal candidiasis (RVVC), according to a review in the Journal of Fungi.